|
|
|
|
|
Emerging Technologies: Topical NSAIDs for Pain
|
Course Description
|
|
|
Nonsteroidal anti-inflammatory drugs (NSAIDs) and
cyclooxygenase-2 selective inhibitors (coxibs) are effective
analgesic and anti-inflammatory drugs, and an important part
of the pharmacologic approach to pain relief. However,
nonselective NSAIDs (NS-NSAIDs) are associated with well
recognized upper and lower gastrointestinal (GI) adverse
effects. While coxibs are differentiated by lower reported
rates of GI complications, all these drugs may be associated
with increased risk of cardiovascular harm. Serious GI and
cardiovascular events may be rare, but they are important
because they may not be reversible and can be life-threatening.
The recognition of the magnitude of risk for both NS-NSAIDs
and coxibs has increased focus on the use of nonsystemic
topical NSAIDs to address certain safety concerns and provide
physicians with expanded options to treat pain. Topical
administration of NSAIDs offers enhanced delivery of
therapeutic drug concentrations to the target tissues to relieve
localized pain, but with potentially fewer systemic adverse
effects due to lower systemic absorption, as well as less
potential for drug-drug interactions and absence of the firstpass
hepatic effect.
|
|
|
|
top
|
|
|
To Receive A Certificate
|
|
|
|
Review the material in the Course Presentations section.
|
|
|
|
Complete the CME Posttest with a score of 7 out of 10 questions correct.
|
|
|
|
You will then be asked to register and complete a brief course evaluation.
|
|
|
|
A certificate will be automatically generated for you online.
|
|
|
|
|
|
|
|
Course Objectives
|
|
|
After participating in this educational activity, participants will be better able to:
• Summarize the clinical trial evidence, and clinical
experience, for the analgesic efficacy of locally applied
topical NSAIDs
• Discuss the relative safety profile, including the risk,
extent, and clinical relevance of potential cutaneous and
systemic adverse reactions of topical NSAIDs
• Differentiate the pharmacokinetic characteristics and
mechanisms of action of topical NSAID compounds
• Identify patients who would most benefit from topical
NSAIDs to determine where these drugs fit in the
armamentarium for pain management
|
|
|
|
top
|
|
|
|
|
Target Audience
|
|
|
|
Physicians, Nurse Practitioners, Nurses, Pharmacists, and Physician Assistants
|
|
|
|
top
|
|
|
|
|
Method of Participation
|
|
|
1. Review the Emerging Technologies: Topical NSAIDs for Pain monograph.
2. Successfully complete the post-test (70% accuracy).
3. Complete the evaluation and registration information.
4. Print your certificate online.
|
|
|
|
top
|
|
|
|
|
Accreditation
|
|
|
Physicians
This activity has been planned and implemented
in accordance with the Essential Areas and Policies of the
Accreditation Council for Continuing Medical Education
(ACCME) through the joint sponsorship of the University of
Nebraska Medical Center, Center for Continuing Education
(UNMC CCE) and PharmaCom Group.
The UNMC CCE is accredited by the ACCME to provide
continuing medical education for physicians.
The UNMC CCE designates this educational activity for a
maximum of 1.0 AMA PRA Category 1 Credit™. Physicians
should only claim credit commensurate with the extent of
their participation in the activity.
Nurses
The UNMC College of Nursing Continuing Nursing
Education is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is provided for 1.0 contact hours under ANCC
criteria. Provided for 1.2 contact hours under Iowa Provider
#78. Provider approved by the California Board of Registered
Nursing, Provider #13699 for 1.2 contact hours.
Pharmacists
 The UNMC CCE is accredited by the
Accreditation Council for Pharmacy Education (ACPE)
as a provider of continuing pharmacy education. The
ACPE provider number is 447-999-09-067-H04-P. To receive
the 1.0 contact hour of continuing education credit,
pharmacists should complete the activity requirements and
evaluation at the conclusion of the teleconference. Approval
is valid from the initial release date of January 15, 2009.
The expiration date is January 15, 2010. A statement of
credit will be available for printing online upon completion of
the post-test with a score of 70% or better.
|
|
|
|
top
|
|
|
|
|
|
|
Disclaimer
|
|
|
|
The content and views presented in this educational activity
are those of the faculty and do not necessarily reflect those
UNMC CCE, or PharmaCom Group, Inc. This material is
prepared based upon a review of multiple sources of
information, but it is not exhaustive of the subject matter.
Therefore, health care professionals and other individuals
should review and consider other publications and materials
on the subject matter before relying solely upon the
information contained in this educational activity. The reader
is also urged to consult the full prescribing information on
any drug mentioned in this publication for recommended
dosage, indications, contraindications, warnings, precautions,
and adverse effects before prescribing any medication. This
is particularly important when a drug is new or infrequently
prescribed.
|
|
|
|
top
|
|
|
|
|
Off-Label Usage Disclosure
|
|
|
|
This activity contains information about commercial
products/devices that are unlabeled for use or investigational
uses of products not yet approved.
|
|
|
|
top
|
|
|
|
|
Support
|
|
|
|
Supported by an unrestricted educational grant from ALPHARMA Pharmaceuticals.
|
|
|
|
top
|
|
|
|
|
|
|
